The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial
Open accessAbstract
Importance: Polypoidal choroidal vasculopathy (PCV) is a common subtype of exudative age-related macular degeneration among Asian individuals. To our knowledge, there are no large randomized clinical trials to evaluate intravitreal ranibizumab, with and without verteporfin photodynamic therapy (vPDT), for the treatment of PCV. Objective: To compare the efficacy and safety of combination therapy of ranibizumab and vPDT with ranibizumab monotherapy in PCV. Design, Setting, and Participants: A double-masked, multicenter randomized clinical trial of 322 Asian participants with symptomatic macular PCV confirmed by the Central Reading Center using indocyanine green angiography was conducted between August 7, 2013, and March 2, 2017. Interventions: Participants were randomized 1:1 to ranibizumab, 0.5 mg, and vPDT (n = 168; combination therapy group) or ranibizumab, 0.5 mg, and sham PDT (n = 154; monotherapy group). All participants received 3 consecutive monthly ranibizumab injections, followed by a pro re nata regimen. Participants also received vPDT/sham PDT on day 1, followed by a pro re nata regimen based on the presence of active polypoidal lesions. Main Outcomes and Measures: Step 1 assessed whether combination therapy was noninferior (5-letter margin) to monotherapy for change in best-corrected visual acuity from baseline and superior in complete polyp regression. If noninferiority was established, step 2 assessed whether combination therapy was superior to monotherapy measured by best-corrected visual acuity change at month 12. Results: Baseline demographics of the 322 participants were comparable between the treatment groups. Mean (SD) age of the patients was 68.1 (8.8) years, and overall, 69.9% of the patients were men. At baseline, the overall mean best-corrected visual acuity and mean central subfield thickness were 61.1 letters and 413.3 μm, respectively. At 12 months, mean improvement from baseline was 8.3 letters with combination therapy vs 5.1 letters with monotherapy (mean difference, 3.2 letters; 95% CI, 0.4-6.1), indicating that combination therapy met the predefined criterion for noninferiority as well as being superior to monotherapy (P = .01). Combination therapy was also superior to monotherapy in achieving complete polyp regression at month 12 (69.3% vs 34.7%; P < .001). Over 12 months, the combination therapy group received a median of 4.0 ranibizumab injections compared with 7.0 in the monotherapy group. Vitreous hemorrhage was the only ocular serious adverse event (combination therapy group, 1 [0.6%]; monotherapy group, 3 [2.0%]). Conclusions and Relevance: After 12 months, combination therapy of ranibizumab plus vPDT was not only noninferior but also superior to ranibizumab monotherapy in best-corrected visual acuity and superior in complete polyp regression while requiring fewer injections. Combination therapy should be considered for eyes with PCV. Trial Registration: clinicaltrials.gov Identifier: NCT01846273.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY (IPCV)
Yannuzzi, L. A., Sorenson, J., Spaide, R. F., & Lipson, B. (2012) · Retina · doi:10.1097/iae.0b013e31823f992a · Cited by 753
IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY (IPCV)
YANNUZZI, L. A., SORENSON, J., SPAIDE, R. F., & LIPSON, B. (1990) · Retina · doi:10.1097/00006982-199010010-00001 · Cited by 588
Koh, A., Lee, W. K., Chen, L.-J., Chen, S.-J., Hashad, Y., Kim, H., Lai, T. Y., Pilz, S., Ruamviboonsuk, P., Tokaji, E., et al. (2012) · Retina · doi:10.1097/iae.0b013e31824f91e8 · Cited by 587
Self-citationAge-related macular degeneration and polypoidal choroidal vasculopathy in Asians
Wong, C. W., Yanagi, Y., Lee, W.-K., Ogura, Y., Yeo, I., Wong, T. Y., & Cheung, C. M. G. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.04.002 · Cited by 346
Self-citationLaude, A., Cackett, P. D., Vithana, E. N., Yeo, I. Y., Wong, D., Koh, A. H., Wong, T. Y., & Aung, T. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.10.001 · Cited by 334
Self-citationPOLYPOIDAL CHOROIDAL VASCULOPATHY: Evidence-Based Guidelines for Clinical Diagnosis and Treatment
Koh, A. H. C., Chen, L.-J., Chen, S.-J., Chen, Y., Giridhar, A., Iida, T., Kim, H., Lai, T. Y. Y., Lee, W. K., Li, X., et al. (2013) · Retina · doi:10.1097/iae.0b013e3182852446 · Cited by 265
Self-citationHEMORRHAGIC COMPLICATIONS AFTER PHOTODYNAMIC THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY
Hirami, Y., Tsujikawa, A., Otani, A., Yodoi, Y., AIKAWA, H., Mandai, M., & Yoshimura, N. (2007) · Retina · doi:10.1097/01.iae.0000233647.78726.46 · Cited by 157
Oishi, A., Kojima, H., Mandai, M., Honda, S., Matsuoka, T., Oh, H., Kita, M., Nagai, T., Fujihara, M., Bessho, N., et al. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.05.024 · Cited by 150
Tan, C. S., Ngo, W. K., Chen, J. P., Tan, N., & Lim, T. H. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305674 · Cited by 142
Self-citationClinicopathologic Correlation of Idiopathic Polypoidal Choroidal Vasculopathy
Rosa, R. H., Davis, J. L., & Eifrig, C. W. G. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.4.502 · Cited by 120
Cited by
Age-related macular degeneration
Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31550-2 · Cited by 1,511
Self-citationPolypoidal Choroidal Vasculopathy
Cheung, C. M. G., Lai, T. Y. Y., Teo, K., Ruamviboonsuk, P., Chen, S.-J., Kim, J. E., Gomi, F., Koh, A. H., Kokame, G., Jordan-Yu, J. M., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.08.006 · Cited by 519
Self-citationCentral serous chorioretinopathy: Towards an evidence-based treatment guideline
van Rijssen, T. J., van Dijk, E. H. C., Yzer, S., Ohno-Matsui, K., Keunen, J. E. E., Schlingemann, R. O., Sivaprasad, S., Querques, G., Downes, S. M., Fauser, S., et al. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.07.003 · Cited by 478
Self-citationPolypoidal Choroidal Vasculopathy
Cheung, C. M. G., Lai, T. Y. Y., Ruamviboonsuk, P., Chen, S.-J., Chen, Y., Freund, K. B., Gomi, F., Koh, A. H., Lee, W.-K., & Wong, T. Y. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.11.019 · Cited by 396
Self-citationMettu, P. S., Allingham, M. J., & Cousins, S. W. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100906 · Cited by 370
Metadata
- Authors
- Koh, A., Lai, T. Y. Y., Takahashi, K., Wong, T. Y., Chen, L.-J., Ruamviboonsuk, P., Tan, C. S., Feller, C., Margaron, P., Lim, T. H., Lee, W. K., & for the EVEREST II study group
- Venue
- JAMA Ophthalmology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-11-01
- Volume
- 135
- Issue
- 11
- Pages
- 1206
- ISSN
- 2168-6165 (ISSN-L)
- OpenAlex
- W2763376487
- Cited by
- 301
- References
- 28
- FWCI
- 29.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaophthalmol.2017.4030
- The paper
- Koh, A., Lai, T. Y. Y., Takahashi, K., Wong, T. Y., Chen, L.-J., Ruamviboonsuk, P., Tan, C. S., Feller, C., Margaron, P., Lim, T. H., Lee, W. K., & for the EVEREST II study group. (2017). Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial. JAMA Ophthalmology. https://doi.org/10.1001/jamaophthalmol.2017.4030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.